Events

Measurable residual disease (MRD) assessment plays a critical role in monitoring acute myeloid leukemia (AML) progression and relapse risk. Current standard-of-care approaches, including multiparameter flow cytometry (MFC) and bulk next-generation sequencing (NGS), can miss phenotypic shifts and rare relapse-driving clones because the results represent averaged cellular populations rather than individual cell behavior. Advances in single-cell multiomic analysis now allow simultaneous evaluation of DNA mutations and cell surface proteins at the resolution of individual cells, enabling deeper disease biology characterization.

Topics to be covered

• Limitations of current AML MRD assessment methods
• Comparison of MFC, bulk NGS, and single-cell approaches
• Detection of rare relapse-driving clones using single-cell multiomics
• Clinical study results demonstrating improved MRD sensitivity
• The effect of single-cell MRD analysis on relapse prediction
• Implications for targeted treatment decisions and clinical trial stratification